SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SB-215505

Cat. No.:	HY-18596
CAS No.:	162100-15-4
Molecular Formula:	$C_{19}H_{16}ClN_3O$
Molecular Weight:	337.8
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (74.01 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.9603 mL	14.8017 mL	29.6033 mL
	5 mM	0.5921 mL	2.9603 mL	5.9207 mL
	10 mM	0.2960 mL	1.4802 mL	2.9603 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SB-215505 is a potent and subtype-selective 5-HT_{2B} receptor antagonist with pK_i values of 8.3, 6.77, 7.66 for 5-HT_{2B}, 5-HT_{2A}, 5-HT_{2C}, respectively[1]. SB-215505 increases wakefulness and motor activity in rats[2].

IC_{50} & Target

5-HT_{2B} Receptor	5-HT_{2A} Receptor	5-HT_{2C} Receptor
8.3 (pKi)	6.77 (pKi)	7.66 (pKi)

In Vitro

SB-215505 is 30 fold selective for the 5-HT_{2B} over the 5-HT_{2A} receptor, and only marginally selective over the 5-HT_{2C} receptor[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB-215505 (0.1-1.0 mg/kg; i.p.; two doses) dose-dependently increases wakefulness (W) and decreases IS, PS, SWS-2[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 230-260 g[2]

Dosage:	0.1, 0.3 and 1.0 mg/kg
Administration:	IP; two doses (4 days between two doses)
Result:	Dose-dependently increased wakefulness (W) and decreased intermediate stage of sleep (IS), paradoxical sleep (PS), SWS-2.

REFERENCES

[1]. C Reavill, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.

[2]. Sandor Kantor, et al. Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. J Pharmacol. 2004 Aug;142(8):1332-42.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA